# Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome

> **NCT06437210** · NA · COMPLETED · sponsor: **Catalysis SL** · enrollment: 200 (actual)

## Conditions studied

- Post-COVID-19 Syndrome
- COVID-19
- Dyspnea
- Fatigue
- Cough
- Inflammation

## Interventions

- **DIETARY_SUPPLEMENT:** Viusid Oral Solution
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT06437210
- **Lead sponsor:** Catalysis SL
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-15
- **Primary completion:** 2023-12-15
- **Final completion:** 2024-03-15
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06437210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06437210, "Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06437210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*